Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

582
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
582
Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

577
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
577
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

3.5K
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
3.5K
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

534
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
534
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

501
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
501
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

2.2K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tau20-RETROmapping System Identifies Driver-Like Activation Patterns in Real-Time During Persistent Atrial Fibrillation.

Circulation. Arrhythmia and electrophysiology·2026
Same author

Association between interventional cardiologist practice characteristics, CABG use, and clinical outcomes.

European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery·2026
Same author

Pace and Ablate or Pace Then Ablate: Defining the Risk of Concomitant AV Node Ablation and Pacemaker Implantation Using a Probability Based Approach.

Circulation. Arrhythmia and electrophysiology·2026
Same author

KCNH2 Duplication Variant (c.2164_2181dup) Associated With Sudden Cardiac Death in a Family With Congenital Long QT Syndrome.

The Canadian journal of cardiology·2026
Same author

AI-ECG classification for Brugada syndrome: A study of machine learning techniques to optimise for limited datasets.

PLOS digital health·2026
Same author

Economic evaluation of a novel dual-energy, large focal lattice-tip catheter versus conventional contact-force sensing radiofrequency catheter, for persistent atrial fibrillation ablation, from the English National Health Service perspective.

Open heart·2026

Related Experiment Video

Updated: Mar 15, 2026

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.3K

Ablation therapy for left atrial autonomic modification.

Louisa Malcolme-Lawes1, Belinda C Sandler1, Markus B Sikkel1

  • 1Imperial College, London, UK.

Autonomic Neuroscience : Basic & Clinical
|September 6, 2016
PubMed
Summary
This summary is machine-generated.

Targeting specific autonomic nervous system sites in the atria can trigger atrial fibrillation (AF) ectopy. Ablating these ectopy-triggering ganglionated plexi (GP) sites offers a potential new strategy for paroxysmal AF treatment.

Keywords:
Atrial fibrillationAutonomic nervous systemCatheter ablationHumans

More Related Videos

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Related Experiment Videos

Last Updated: Mar 15, 2026

Robotic Ablation of Atrial Fibrillation
11:21

Robotic Ablation of Atrial Fibrillation

Published on: May 29, 2015

20.3K
Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology
10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

13.9K
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

34.3K

Area of Science:

  • Cardiology
  • Neuroscience
  • Medical Physiology

Background:

  • The autonomic nervous system plays a role in atrial fibrillation (AF) pathogenesis.
  • Neural targeting strategies for AF therapy are underexplored.
  • Conventional methods for locating ganglionated plexi (GPs) rely on inducing AV block, which may not always be effective.

Purpose of the Study:

  • To investigate specific left atrial ganglionated plexi (GP) sites that trigger atrial ectopy.
  • To determine if continuous stimulation of these sites induces AV block.
  • To evaluate the efficacy of ablating these ectopy-triggering GP (ET-GP) sites for AF treatment.

Main Methods:

  • Stimulation of specific left atrial GP sites.
  • Monitoring for induced atrial ectopy and AV block.
  • Ablation of identified ET-GP sites or adjacent pulmonary veins (PVs).

Main Results:

  • Short bursts of stimulation at specific left atrial GP sites triggered fibrillation-inducing atrial ectopy.
  • Continuous stimulation of these ET-GP sites did not consistently induce AV block.
  • Ablation at ET-GP sites or between the ET-GP and PV rendered these sites inactive.
  • ET-GP sites demonstrated anatomical stability.

Conclusions:

  • Specific left atrial GP sites can be identified by their ability to trigger ectopy, not solely by AV block.
  • Ablation of these identified ET-GP sites is a potential therapeutic approach for paroxysmal AF.
  • These findings may inform personalized ablation strategies for AF patients.